Transition from Psoriasis to PsA: Can we Prevent It?

Save

Dr. Aurelie Najm discusses abstract OP0010 presented at Eular 2024 in Vienna, Austria.

JAK Inhibitors For New Indications

Save

Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria.

PsA Treatment Is Earlier Better?

Save

Dr. Aurelie Najm discusses abstract OP0184, presented at Eular 2024 in Vienna, Austria.

EULAR 2024 Daily Recap - Days 1 & 2

Save

Moderated by Dr. Jack Cush and featuring Dr. Yuz Yusof and Dr. Mrinalini Dey

Mechanistic Promise In RA Doesn’t Always M

Save

Dr. David Liew reports on abstracts OP0007 and OP0069 at Eular 2024 in Vienna, Austria.

The Role Of Psychosocial Determinants In T

Save

Dr. Mrinalini Dey reports from Eular 2024 in Vienna, Austria about an abstract she will present during the meeting, POS0309.

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?

Save

Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 Sonelokimab IL 17 A/F nanobody inhibitor LB0005 Izokibep IL17A nanobody inhibitor POS0803 Vunakizumab, another IL17A inhibitor OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib

Voclosporin And Steroids In Lupus Nephriti

Save

Dr. Jack Cush reports on abstract OP0059 presented at Eular 2024 in Vienna, Austria.

3 Big Lupus Themes From EULAR 2024

Save

Dr. Janet Pope discusses three hot topics in lupus at Eular 2024 in Vienna, Austria.

Does B Cell Depletion Matter?

Save

Drs. Yuz Yusof and Ed Vital discuss abstract OP0077 at Eular 2024 in Vienna, Austria.

Do MRI changes at the Spine and SI Joints in Treatment of AxSpA Matter?

Save

Dr. Eric Ruderman discusses abstracts OP0046 and POS0058 presented at Eular 2024 in Vienna, Austria. OP0046 Effect on SI joint structural lesions with ixekizumab POS0058 Effect on SI joint structural lesions with bimekizumab

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?

Save

Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 Sonelokimab IL 17 A/F nanobody inhibitor LB0005 Izokibep IL17A nanobody inhibitor POS0803 Vunakizumab, another IL17A inhibitor OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib